INFORMATION DISCLOSURE				Appli	Application Number			10598774			
				Filing	Filing Date			2006-09-11			
				First I	First Named Inventor Matsu			ui, et al.			
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Art U	Art Unit			2812				
( NOT TOP	subm	ission under 37 CFR	1.99)	Exam	iner Na	me	Unkr	nown			_
				Attorr	Attorney Docket Number		113184-119				
											_
					IIS	PATENTS					
					0.0.	TAILUIS			_		_
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date Name of Patentee of Applicant   Balavant		Columns,Lines where int Passages or Relevant s Appear					
	1										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pi	lease click	the A	dd button.			
			U.S.P.	ATENT	APPLI	CATION P	UBL	CATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>			Name of of cited D	Patentee of Applicant Rel		Rele	ges,Columns,Lines where levant Passages or Relevant ures Appear	
	1										
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n informati	on ple	ease click the Ad	d butte	on.	
				FOREK	SN PA1	ENT DOC	UME	NTS			
Examiner Initial*	Cite No	Foreign Document Numbers	Country Code <sup>2</sup>		Kind Code4	Publicatio Date	n /	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T4
	1										
If you wis	h to a	dd additional Foreign P	atent Do	curnent	citation	informatio	n plea	ase click the Add	butto	n	-
			NON	-PATE	NT LITE	RATURE	DOC	UMENTS			
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seria	al, symp	osium,	catalog, et					T5

Under the Paperwork Reduction Act of 1995, no persons are required to resp

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

pplication Number		10598774		
ling Date		2006-09-11		
rst Named Inventor	Matsu	ui, et al.		
t Unit		2812		
caminer Name	Unknown			
town Deated Member		443404 440		

1	KAS, A.S., WASIELEWSKI, M.R., Approaches to a Molecular Switch Using Photoindused Electron and Energy nafer, Molecular Switches, 2001, pp. 1-3, WILEY-VCH GmbH, Weinhelm, Germany.	С
2	E, M., Photoswitchable Molecular Systems Based on Diarylethenes, Molecular Switches, 2001, pp. 37-38, WILEY- H GmbH, Weinhelm, Germany.	
3	ICZEK, T., DAUB, J., AJAYAGHOSH, A., Optoelectronic Molecular Switches Based on Dihydoszulene- ylhoptatulvene (DHA-VHF), Molecular Switches, 2001, pp. 63-67, WILEY-VCH GmbH, Weinhelm, Germany.	
4	IDA, T., KANAZAWA, A., Liquid Cryfal Photonics: Opto-photochemical Effects in Photoresponsive Liquid Crystals, secular Switches, 2001, pp. 383-384, WILEY-VCH GmbH, Weinhelm, Germany.	

FYAMINER SIGNATURE

Examiner Signature Date Considered

Fi

E

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-latter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST,16 if possible, 4 Applicant is to place a check mark here if English language translation is attached.

#### 

## CERTIFICATION STATEMENT

Diageo e oo 27 CE	0 1 07 and 1 09 to 1	make the engrapeiste	enlaction(e)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CPR 1,97(e)(1).

#### OR

That no tem of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart freeing application, and, to the knowledge of the person signify the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 5 or CPR 1.59(6) more than three months prior to the filting of the information disclosure.

- statement. See 37 ČFR 1.97(e)(2).

  See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_\_\_ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas C. Basso/	Date (YYYY-MM-DD)	2008-12-19			
Name/Print	Thomas C. Basso	Registration Number	46,541			

This collection of information is required by 37 CFR. 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to lie (lead by the USPTO to process) as explication. Conditionalistic is governed by \$5.U.S. C12 and 37 CFR. 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for motiving this burden, should be sent to the Chief Information Officer, U.S. Palent and Trademark Office, U.S. Operationed to Commence, P.O. Box 1450, Alexandric V. V. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandric V. V. 2231-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-57) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. A coordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is \$5 U.S.C. 2(b)(2); (2) furnishing of the information solicide that: (1) the general authority for the collection of this information is \$5 U.S.C. 2(b)(2); (2) furnishing of the information solicide to evoluting; and (3) the principal purpose for which the information is set by the U.S. Patient and Trademan (Chine is to process and/or examine your submission related to a patient speciation or patient. If you do not furnish the requested process and the processing of the patient processing or patient. They do not furnish the requested requirement of the patient of the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (S U.S.C. 552) and the Privacy Act (S U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement necotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privary Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hishher designer, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under subnety of 44 U.S.C. 2504 and 2508. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall be made in accordance or the control of the contr
- A rocord from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or susuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.